Copyright
©The Author(s) 2024.
World J Diabetes. Jul 15, 2024; 15(7): 1518-1530
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1518
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1518
Groups | Improvement | Effective | Ineffective | Overall efficacy rate |
Control group (n = 51) | 16 (31.37) | 20 (39.22) | 15 (29.41) | 36 (70.59) |
Study group (n = 51) | 27 (52.94) | 19 (37.25) | 5 (9.81) | 46 (90.19) |
χ2 | 6.220 | |||
P value | 0.013a |
- Citation: Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety. World J Diabetes 2024; 15(7): 1518-1530
- URL: https://www.wjgnet.com/1948-9358/full/v15/i7/1518.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i7.1518